Publications (43) Alfonso Jesús Domínguez-Gil Hurlé publications

filter_list Pharmacology (medical)

2010

  1. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 4, pp. 948-954

  2. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy

    Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489

2007

  1. Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 5, pp. 1074-1079

  2. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain

    Clinical Drug Investigation, Vol. 27, Núm. 3, pp. 197-205

  3. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

    Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285

2006

  1. Prevalencia y factores asociados a los acontecimientos adversos prevenibles por medicamentos que causan el ingreso hospitalario

    Farmacia Hospitalaria, Vol. 30, Núm. 3, pp. 161-170

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data

    Biopharmaceutics and Drug Disposition, Vol. 20, Núm. 5, pp. 233-240

  2. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients

    Haematologica, Vol. 84, Núm. 3, pp. 231-236

1997

  1. Carbamazepine population pharmacokinetics in children: Mixed-effect models

    Therapeutic Drug Monitoring, Vol. 19, Núm. 2, pp. 132-139

1996

  1. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

    Clinical Pharmacology and Therapeutics, Vol. 60, Núm. 3, pp. 332-340

1994

  1. Comparative study of the influence of Ca2+ on absorption parameters of ciprofloxacin and ofloxacin

    Journal of Antimicrobial Chemotherapy, Vol. 34, Núm. 1, pp. 119-125

1993

  1. Contribution of biopharmaceutics and pharmacokinetics to improve drug therapy

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 18, Núm. 1, pp. 1-5

1992

  1. A method for the calculation of bioavailability in slow release formulations in the presence of within-individual variability

    International Journal of Pharmaceutics, Vol. 86, Núm. 2-3, pp. 123-130

1991

  1. Bioequivalence of a new formulation of flecainide acetate.

    European journal of drug metabolism and pharmacokinetics, Vol. Spec No 3, pp. 216-220

1990

  1. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary

    American Journal of Hospital Pharmacy, Vol. 47, Núm. 9, pp. 2002-2006

1988

  1. Discrimination of kinetic models in heteroscedastic parametric estimation of bentazepam following multiple dosing

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 26, Núm. 7, pp. 335-338